Karl Gubitz

Chief Financial Officer, argenx SE

Search every verified Karl Gubitz interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Karl Gubitz, Chief Financial Officer of Argenx, discussed the company's growth strategy and financial position in a March 2026 podcast appearance. He stated that the finance team's role is to support the company's innovation mission and described scaling as "scaling capabilities, not scaling the organization," citing manufacturing decisions as an example. Gubitz noted that Argenx is now profitable due to revenues from Vyvgart, allowing the company to fund operations without annual fundraising, while balancing risk-taking with long-term sustainability. He also highlighted a past decision to develop a self-injection device for Vyvgart as a differentiator, asserting that Argenx is the only company offering such a delivery method for FcRn inhibitors. In a December 2023 appearance at the Morgan Stanley HealthCare Conference, Gubitz addressed commercial and pipeline topics. He said Argenx had not provided sales guidance due to variables such as new indications, geographical expansion, and pricing in new markets like China, though the company does provide cash burn guidance. He described the CIDP study for Vyvgart as the largest and cleanest ever conducted, with representation across treatment-naive, steroid-experienced, and IVIG-experienced patient subsets. Gubitz also discussed the potential for Vyvgart in additional indications, including ITP and other conditions, and stated that the pricing for myasthenia gravis was set to remain compatible with expanding use in CIDP.